Escalating dosing regimen for effecting weight loss and treating obesity
US8895057B2 · kind B2 · utility
3Cited by
36References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 8, 2013 |
| Grant date | Nov 25, 2014 |
| Priority date | — |
| Expiry date | Oct 8, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.